JHVEPhoto/iStock Editorial via Getty Images Novo Nordisk (NVO) announced Thursday that the U.S. Food and Drug Administration (FDA) declined to approve its once-weekly insulin product, insulin icodec, targeted at patients with diabetes mellitus (DM). Issuing a complete response letter, the regulator has requested information related to its manufacturing process andContinue Reading
JHVEPhoto/iStock Editorial via Getty Images Novo Nordisk (NVO) said that ocedurenone, under investigation for uncontrolled hypertension in chronic kidney disease patients, missed its primary endpoint in a phase 3 trial. That endpoint was change in systolic blood pressure from baseline to week 12. As a result, the Danish pharma isContinue Reading
Victor Golmer/iStock Editorial via Getty Images Novo Nordisk (NVO) will invest $4.1B to build a second fill and finish manufacturing facility in Clayton, N.C. focused on injectables medications, including current and future ones for obesity. The development comes as Novo, which makes the weight loss drug Wegovy (semaglutide), and rivalContinue Reading
CR Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO), which already have blockbusters with their weight loss drugs Zepbound (tirzepatide) and Wegovy (tirzepatide), are likely to dominate the market even if other drugs are approved, according to two Street analysts. Holly Morris, managing director at J.P. Morgan Asset Management focused onContinue Reading
